Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1/2 4Phase 3 1

Status

Terminated 2Completed 2

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Genitourinary 1Gastrointestinal 1

Conditions

Advanced Cancer 2Urinary Bladder Neoplasms 1Non-Muscle Invasive Bladder Neoplasms 1Advanced Gastric Cancer 1

Interventions

Cyclophosphamide 517Bevacizumab 488Carboplatin 424pembrolizumab 388Paclitaxel 385Gemcitabine 372Cisplatin 366Docetaxel 323Rituximab 316Radiotherapy 296Nivolumab 247Doxorubicin 243Dexamethasone 240Fluorouracil 225Capecitabine 214Oxaliplatin 211Erlotinib Hydrochloride 206fludarabine phosphate 201Etoposide 188Cetuximab 186Lenalidomide 177Pemetrexed 176Bortezomib 174Trastuzumab 173Filgrastim 171fludarabine 166Prednisone 166Leucovorin 166Cytarabine 166Irinotecan 161

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2 × Has results × linrodostat × Clear all
NCT02935634 2023-06-09

FRACTION-GC

Bristol-Myers Squibb

Phase 2 Completed
190 enrolled 25 charts
Gastrointestinal

Advanced Gastric Cancer

NCT03519256 2023-06-01

CheckMate 9UT

Bristol-Myers Squibb

Phase 2 Terminated
142 enrolled 20 charts
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT02996110 2022-12-19

FRACTION-RCC

Bristol-Myers Squibb

Phase 2 Completed
182 enrolled 23 charts

Advanced Cancer

NCT02750514 2021-03-22

FRACTION-Lung

Bristol-Myers Squibb

Phase 2 Terminated
295 enrolled 21 charts

Advanced Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡